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INTRODUCTION
This short version complies with the intention ex-
pressed in the methodological introduction to the
full text Italian Guidelines for the use of antiretro-
viral drugs and the diagnostic-clinical management
of people with HIV-1 infection. By definition, this
version should not be considered completely ex-
haustive with respect to the full text version of
the Guidelines, that are available at web site:
http://www.salute.gov.it/imgs/C_17_pubbli-
cazioni_1301_allegato.pdf.
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The aim of this version is simply to render certain
concepts expressed in the document more usable,
by specific circulation in booklet form, inviting
the reader to refer to the extended version for fur-
ther information and full details.
It was decided not to discuss in toto in this ver-
sion certain fundamental parts of the extended
versions such as the populations requiring spe-
cial attention (elderly, women, immigrants, chil-
dren), the conditions requiring special attention
(drug and/or alcohol addiction, detention) or the
situations requiring special attention (trans-
plants). 
For all these populations, conditions or situations,
it should be referred at the full text version of the
Guidelines.
Lastly, it was decided to refer the reader to the
extended version for all bibliographic citations,
except for the essential references cited at the end
of this version.
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PATIENT ASSESSMENT 
AND PREPARATION
The initiation of combination antiretroviral ther-
apy (cART) should be considered a crucial mo-
ment in the management of HIV infection which
requires:
- particular competency of the attending physi-
cian;
- comprehension and agreement on the part of
the patient.
Physician-patient communication and the quali-
ty of their relationship can influence acceptance
of this new phase. In particular, the capacity to es-
tablish a rapport of trust in the relationship con-
ditions the willingness of the patient to accept
and agree to the therapeutic prescription.
It is thus fundamental to assess the individual’s
degree of receptiveness, which depends on social,
cognitive and emotional variables, and affects the
capacity to understand the the information pro-
vided. It is emphasized that information skills de-
pend not only on talking skills but also on the ca-
pacity to listen and understand.
Recommendations [AIII]:
- Offer the patient an interview in private.
- Guarantee the time necessary for comprehen-
sion, listening to and answering the patients’
questions.
- Explain in detail why it is important and/or nec-
essary to commence HAART.
- Inform the patient of the treatment options
with a discussion of the benefits and risks of
each approach.
VIRO-IMMUNOLOGICAL DIAGNOSTICS
The diagnosis of chronic HIV-1 infection is de-
fined by the presence of HIV-1 antibodies, con-
firmed by immunoblotting.
The plasma HIV-RNA concentration (viremia or
viral load) is used as a surrogate marker and
serves to forecast the risk of clinical progression
of the infection (prognostic marker) and assess
the degree of the therapeutic response (efficacy
marker). The principal objective of combination
antiretroviral therapy in all patients is a reduc-
tion in viremia to undetectable levels (unde-
tectability), and the maintenance of virological
suppression for as long as possible [AII]. To date,
the guidelines suggest using a limit value of
greater than 50 copies/mL as the criteria for vi-
rological failure assessment [AI].
The use of resistance tests is currently recom-
mended both for the choice of the first line ther-
apy [AII] and for the choice of alternative thera-
py in the case of virological failure [AI].
Level of evidence
LEVEL I
The data are collated from at least one controlled, randomized study with sufficient
potency or from s meta-analysis of controlled studies.
LEVEL II
The data are collated from non-randomized studies or from cohort observational
studies.
LEVEL III Recommendation based on case reviews or agreement among experts.
Degree of recommendation
A Highly recommended.
B Moderately recommended.
C Optional.
TABLE 1 - Degree of recommendation and level of evidence
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The use of genotype assays is preferable to phe-
notype assays. Resistance assays should be in-
terpreted with the use of viral genetic sequences
with management algorithms (virological inter-
pretation). Ideally, resistance assays should be in-
terpreted by clinician with experience in utiliz-
ing additional parameters in the assessment, such
as previous resistance tests, immunovirological
and therapeutic data (virological and clinical in-
terpretation). The best interpretation can be ob-
tained in the latter conditions [AII]. An addition-
al assessment with phenotype tests may prove
useful for patients with complex resistance situ-
ations [BIII].
The data available to date indicate the utility of
genotype or phenotype test for assessment of the
prevalent viral strain for the purpose of using
CCR5 antagonists [AII]. The simplicity of per-
formance, lower costs, and the reliability of the
test favour the genotypic assay [BII].
Quantification of the CD4+ lymphocyte count is
an essential prognostic marker. The CD4 count
determines the indication for initiation of anti-
retroviral therapy as well as the intiation or sus-
pension of prophylaxis of opportunistic infections
[AI].
The CD4+ count should be repeated 1 month af-
ter commencing antiretroviral therapy and, sub-
sequently every 3-4 months in the stable phase. In
patients with unsatisfactory immunological re-
covery (<50-150 cells/µL per year), immunologi-
cal monitoring should be more frequent (2/3
months) [BI].
The percentage CD4+ count must be assessed to-
gether with the total CD4+ count as an immune
system function marker (CD4+ percentages be-
low 14% are associated with an increased risk of
opportunistic infections, approximately equiva-
lent to a CD4+ count of <20 cells/L) [AII].
WHEN TO START
Condition Recommendation for treatment Strength/evidence
Acute infection or recent seroconversion Not recommended
Acute infection with severe symptomatology Highly recommended* [AII]
*If therapy is initiated, inclusion in a controlled clinical study is recommended where possible [BIII]
TABLE 2 - When to start in patients with acute infection.
TABLE 3 - When to start in patients with chronic infection.
→
Clinical condition Lymphocyte T
CD4+ count
Recommendation for treatment Strength/evidence
AIDS Any value Highly recommended [AI]
HIV-related diseases (group B of 1993
CDC definition)
Any value Highly recommended [AII]
Pregnancy Any value Highly recommended [AI]
HIV-associated nephropathy (HIVAN) Any value Highly recommended [AII]
Non AIDS-definining cancers Any value Highly recommended [AII]
HIV-associate neurocognitive disorders
(HAND)
Any value Highly recommended [AII]
Chronic HBV hepatitis requiring treat-
ment*
Any value Highly recommended with agents active
against both HIV and HBV
[AII]
Elevated risk of secondary HIV trans-
mission
Any value Moderately recommended only in the case
of a motivated patient
[BII]
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→ Clinical condition Lymphocyte T CD4+ count Recommendation for treatment Strength/evidence
Asymptomatic CD4+: ≤201-350 cells/µL Highly recommended [AII]
Asymptomatic CD4+: 351-500 cells/µL Moderately recommended in all patients
Highly recommended in the presence of:
a) HIV-RNA >100.000 copies/mL
b) decrease in CD4+ >100 cells/ L per year
c) age >50 years
d) chronic hepatitis from HCV
Moderately recommended in the case of:
e) elevated cardiovascular risk: diabetes
mellitus or previous cardiovascular event,
or elevated risk in the next 10 years (esti-
mate with Framingham algorithm)
[BII]
[AII]
[AII]
[AII]
[AII]
[BIII]
Asymptomatic CD4+ >500 cells/µL Not recommended, except in cases of a
highly motivated patient and/or in the pre-
sence of the factors indicated above at
items a), b), c), d), e), where it is optional.
[CII]
*In cases in which there is indication of HBV treatment by nucleotide/nucleoside analogues.
TABLE 4 - Timing of initiation of antiretroviral therapy in patients with AIDS or non-AIDS defining
neoplasias (treatment Highly recommended [AI]).
Clinical condition Timing of commencement of antiretroviral therapy Strength/evidence (referred to the timing
of commencement of arv therapy)
- Multifocal
progressive
leukoencephalopathy
- HIV
encephalopathy
- Wasting syndrome
- Enteritis from
Cryptosporidium or
Microsporidia
Immediate initiation highly recommended [AII]
Pneumonia from 
P. jiroveci
Highly recommended initiation within 2 weeks of
diagnosis
[AI]
Pulmonary
tuberculosis
Highly recommended initiation within 3 months of
anti-tubercular therapy
[AI]
Tubercular
meningitis
Moderately recommended initiation after 2 months of 4
drug anti-tubercular therapy
[BI]
Cryptococcal
meningitis
Highly recommended initiation upon completion of
induction therapy for opportunistic infection
[AI]
Disease from atypical
mycobacteria
Optional, where possible, initiation within 4 weeks of
treatment for mycobacteriosis
[CIII]
CMV Disease Optional, where possible, initiation upon completion of
induction therapy for opportunistic infection
[CIII]
Patients with
neoplasia
Highly recommended immediate initiation and, in all
cases recommended prior to initiation of chemotherapy
[AII]
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WHAT TO START WITH
The choice of initial therapy in patients with HIV
must be tailored to:
1. Available data on the characteristics of the dif-
ferent agents and drug combinations (viro-
logical and immunological efficacy, confor-
mulation/convenience, toxicity and tolerabili-
ty, genetic barrier, prior clinical use).
2. Factors regarding the overall clinical status,
genetic factors, and characteristics of the pa-
tient including:
- Comorbidities (cardiovascular disease, he-
patic, renal disease, neuro-cognitive disor-
TABLE 5 - Conditions for classification of drugs and combinations.
Conditions for classification of drug/combination
Drug/combination satisfying the majority of the following conditions: it is considered “standard of care”; in at least one ran-
domized study it has shown to be at miniumum non inferior to “standard of care”; is compact/ convenient; it has a favou-
rable toxicity and tolerability profile; it has demonstrable extensive clinical use.
Drug/combination which does not satisfy all the first choice criteria but which may represent, in specific cases, the best
choice for a given patient (profiles of toxicity, pharmacological interactions with concomitant treatments).
Drug/combination considered efficacious, in cases where the patient does not tolerate or is unable to take first choice or
alternative drugs/associations.
To date, data in the scientific literature reports, almost exclusively, the results obtained with combination regimens consi-
sting of: a backbone of nucleos(t)ides (NRTI) and a base of a third drug from another class. Indications for the choice of
drugs constituting the backbone may be determined on the basis of available coformulations rather than the single drug.
TABLE 6 - Backbone nucleos(t)ide. First choice and alternatives.
Choices Pharmacological association
[Strength/evidence]
Comment
First Choice TDF/FTC* [AI] Superior to ZDV/3TC; co-formulated; QD.
TDF/3TC* [BI] Only non-inferior to d4T/3TC, greater risk of resistances at failure compa-
red to TDF/FTC (but not by direct comparison); non co-formulated; QD.
ABC/3TC**[BI] Only non-inferior to ZDV/3TC; inferior to TDF/FTC in presence of elevated
viral loads; in patients with viremia greater than 100,000 copies/mL it
must not be used in combination with ATV/r or EFV, but only with LPV/r;
lack of data on association with DRV/r and RAL; higher CV risk; co-formu-
lated; QD.
Alternative AZT/3TC [BI] Less effective; greater toxicity; lower genetic barrier; lack of data on asso-
ciation with DRV/r, ATV/r and RAL; co-formulated; non QD.
ders, psychiatric illness, concurrent infec-
tions and/or conditions such as drug
abuse/dependence, etc.);
- Potential adverse effects of the drugs used;
- Potential drug-drug interactions;
- Current or pregnancy potential;
- Genotype resistance test;
- Likelihood of adherence to treatment;
- Acceptability of regimen (number of pills,
number of administrations, assumption
modality);
- CD4+ lymphocytes count, if use of nevirap-
ine is considered;
- HLA-B 5701, if use of abacavir is considered.
To date, data in the scientific literature reports, al-
most exclusively, the results obtained with com-
bination regimens consisting of: a backbone of
nucleos(t)ides (NRTI) and a base of a third drug
from another class. Indications for the choice of
drugs constituting the backbone may be deter-
mined on the basis of available coformulations
rather than the single drug.
→
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Choices Pharmacological association
[Strength/evidence]
Comment
Acceptable ddI/3TC or FTC*** [CI] ddI/3TC/EFV non-inferior to ZDV/3TC/EFV; greater toxicity than ddI, ab-
sorption significantly determined by food; non co-formulated; QD.
*Tenofovir should not be used in patients with renal insufficiency.
**Abacavir can only be used in HLA-B*5701 negative patients (screening recommended [AI]) and clinical HSR surveillance must be maintained in these pa-
tients; use with care in patients at elevated risk of cardiovascular disease (Framingham risk score > 20%): even though observational data on increased car-
diovascular risk with ABC not consistent and the biological mechanism insufficiently clarified; do not initiate concomitant treatment with nevirapine due to
augmented risk of hypersensitivity reactions (HSR).
***Didanosine + FTC/3TC only in association with EFV; with ATV excess of early virological failures; long-term mitochondrial toxicity (pancreatitis, peripheral
neuropathy, lactic acidosis), hepatic and endothelial (excess of myocardial infarction, non cirrhotic portal hypertension); not indicated in conjunction with
ribavirin (see HIV/HCV co-infection chapter).
→
TABLE 7 - Third drug, first choice.
In regards to choice of class for the third agent, consideration should be given to long-term efficacy data, the genetic
barrier to resistance and the long-term sequencing strategy.
Choices Drug [Strength/ evidence] Comment
First Choice
EFV* (600 mg) [AI] Standard of care in the majority of randomized clinical studies in which it
has consistently shown equivalence or superiority; neuro-psychiatric dis-
turbances in the first 12 weeks administration; QD.
ATV/r (300/100 mg QD) [AI] Elevated tolerability. Non-inferior to EFV; non-inferior to LPV/r with lower
gastrointestinal toxicity and dyslipidaemia. Lack of data on the association
with ZDV/3TC; hyperbilirubinaemia; QD.
NVP** (400 mg) [BI] Criterion of non inferiority to EFV not reached; non-inferior to ATV/r (48
weeks) but greater toxicity; best lipid profile with respect to ATV/r; equiva-
lent to LPV/r (>48 weeks) but greater toxicity. Lack of data on the associa-
tion with ABC/3TC. BID; QD optional (not authorized in Italy).
DRV/r (800/100 mg QD) [BI] Limited use in naïve patients. Non-inferiority demonstrated only with re-
spect to LPV/r; lack of comparative studies with EFV or ATV/r. Lower ga-
strointestinal toxicity and dyslipidaemia than LPV/r. Lack of data on the as-
sociation with ABC/3TC and ZDV/3TC.
LPV/r*** (800/200 mg QD or
400/100 BID) [BI]
Inferior to EFV at 96 weeks. Standard of care in the majority of comparati-
ve studies with other PIs; sole co-formulated PI; greater toxicity; 200 mg of
RTV; greater dyslipidaemia and gastrointestinal disturbances than DRV/r
and ATV/r; higher number of pills; BID (QD non-inferior to BID but only 48
weeks; QD inferior to DRV/r QD).
RAL (400 mg BID) [BI] Limited use in naïve patients; non-inferior to EFV with fewer adverse events
and dyslipidaemia; Lack of data on the association with ABC/3TC and
ZDV/3TC; BID.
*EFV must not be used during first trimester of pregnancy, in women planning pregnancy or who may become pregnant due to lack of contraceptive use.
**NVP must not be used in women with CD4+ >250 cells/µL or in men with CD4+ >400 cells/µL (higher risk of hepatotoxicity and/or cutaneous rash); in the
first two weeks of therapy utilize the induction dose 200 mg/day. Some pilot studies indicate excess early virological failure with use of TDF+3TC+NVP QD:
this combination should therefore be avoided, with the TDF/FTC+NVP combination, both QD and BID were found efficacious in randomized studies. Use
with care in patients with hepatic viral co-infection.
***LPV/r 400/100 BID is the first choice therapy in pregnant women.
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TABLE 8 - Third drug, alternative, acceptable choices
→
Choices Drug [Strength/ evidence] Comment
Alternative FPV/r* (700/100 mg BID) [BI] Non-inferior to LPV/r BID at 96 weeks with same toxicity profile; BID, 200
mg RTV and higher number of pills; QD not authorized in Italy.
SQV/r (1000/100 mg BID) [BI] Non-inferior to LPV/r (but less hypertriglycerideamia), but with only 48
weeks follow-up; 200 mg RTV; higher number of pills; BID.
Acceptable ATV** (400 mg QD) [CI] Non-inferiority study with small sample size does not confirm non-inferio-
rity to ATV/r at 96 weeks; greater virological failures; studied only in asso-
ciation with d4T+3TC.
Maraviroc*** [CI] Non-inferior to EFV only in one post-hoc analysis; BID; studied only with
AZT+3TC.
*FPV/r 1400/200 mg QD [BI]) 48 week studies compared with NFV, daily dosing not authorized in Italy; FPV/r 1400/100 mg QD [BI]) small study, dosing not
authorized in Italy.
**ATV without ritonavir not authorized in Italy; not to be used in any case without ritonavir booster when in concomitant use with tenofovir (except where
plasma levels can be verified by TDM, see specific chapter) and/or efavirenz. The panel has decided to await new data before making a definitive recom-
mendation.
***Maraviroc not registered in Italy for first line use. In naïve patients it demonstrated non-inferiority at 96 weeks against efavirenz in only one post-hoc analy-
sis. The agent was studied exclusively in association with AZT+3TC at a dosage of 300 mg BID. Good efficacy is to be expected with a non-thymidine analo-
gue backbone. Nevertheless, the panel has decided to await new data before making a definitive recommendation.
TABLE 9 - Comparison of virological and immunological efficacy, convenience and genetic barrier of different
antiretroviral regimens used in the treatment of naïve patients (first and alternative choice).
NUCLEOS(T)IDIC BACKBONE
Rank Virological efficacy Immunological
efficacy
Compactness/convenience
(number of pills and
administrations, co-formulation)
Extensive
clinical use
Genetic barrier (lower
frequency of resistance
at failure)
1 TDF/FTC
TDF+3TC
TDF/FTC
TDF+3TC
ABC/3TC
TDF/FTC
ABC/3TC
TDF/FTC
TDF+3TC
ABC/3TC
AZT/3TC
TDF/FTC
ABC/3TC
2 ABC/3TC ddI+3TC
AZT/3TC
TDF+3TC
ddI+3TC
ddI+3TC TDF+3TC
AZT/3TC
ddI+3TC
3 AZT/3TC
ddI+3TC [3, 14]
AZT/3TC
THIRD DRUG
1 EFV
ATV/r
DRV/r
RAL
ATV/r, LPV/r,
DRV/r, FPV/r,
SQV/r 
EFV EFV
LPV/r
ATV/r
DRV/r
ATV/r
LPV/r
FPV/r
SQV/r
2 LPV/r
FPV/r
SQV/r
NVP (48 weeks,
non inferior to
ATV/r, equivalent
to LPV/r)
EFV, NVP, RAL 
SQV/r (48 weeks) 
ATV/r NVP
FPV/r
SQV/r
EFV
NVP
RAL
HOW TO CONTINUE: SIMPLIFICATION
Therapeutic simplification involves the modifi-
cation of at least one drug in the regimen and is
intended to improve quality of life by increasing
tolerability, reducing number of pills/adminis-
trations, and reducing pharmacological interac-
tions. By improving adherence, simplification al-
so intends to reduce the risk of therapeutic fail-
ure. Reduced medium to long-term toxicities is
a possible indication for simplification of thera-
peutic regimens. This section only considers sim-
plification in conditions of virological suppres-
sion (HIV-RNA <50 copies/mL).
Indications for simplification
- Documented toxicity.
- Presence of side-effects.
- Planned pregnancy.
- Desire to simplify therapy.
- Current regimen no longer recommended.
- Prevention of long-term toxicity (pre-emptive
switch).
- Current therapy may worsen co-morbidities or
clinical manifestations linked with aging.
- Interactions with other drugs.
- Indication to treat other infections (TB, HBV,
HCV, etc.).
Simplification strategies in patients with
stably suppressed viremia
- Intra-class simplification in the case of side-ef-
fects to single agents, including improvement
dyslipidaemia and/or lipodystrophy.
- Simplification to once daily administration of
NRTI or PI/r administered BID in order to im-
prove adherence.
- Simplification from PI/r to EFV, NVP or RAL to
prevent or improve metabolic toxicity and im-
prove adherence (only in cases with no prior vi-
rological failure and full activity of NRTIs utilized).
- Simplification to monotherapy with PI/r (DRV/r
and LPV/r with reintroduction of the 2 NRTIs
in the case of rebound to low viremia) in the
case of toxicity or reduced NRTI tolerability:
only in selected patients with no history of vi-
rological failure, with undetectable viremia (<50
copies/mL) for at least 6 months, good im-
munological recovery and CD4+ nadir >100
cells/µL, on treatment with PI/r and without PI
resistance mutations as determined prior to ini-
tiation of antiretroviral treatment. In all cases,
close virological monitoring is required for ear-
ly assessment of possible failure.
- Simplification from enfuvurtide to raltegravir
for ease of administration and elimination of cu-
taneous side-effects in patients with no previous
treatment experience with integrase inhibitors.
MANAGEMENT OF THERAPEUTIC FAILURE
Despite the efficacy of current antiretroviral treat-
ment, a measurable proportion of patients expe-
rience therapeutic failure due to a suboptimal vi-
rological response (virological failure), unsatis-
factory immunological response (immunological
failure) and, to a lesser extent, clinical progres-
sion (clinical failure). Clinical failure is defined by
the onset of HIV-related clinical events in patients
on antiretroviral therapy for at least three months,
after the exclusion of immune reconstitution syn-
drome. Immunological failure may be defined as
a failure to recover and/or maintain (a normal?)
CD4+ lymphocytes count, despite virological sup-
pression. Virological failure is defined by lack of
suppression of HIV viremia to values below 50
copies/mL of plasma HIV-RNA (undetectability)
24 weeks after treatment initiation or as a rise in
viral replication (rebound), confirmed by two con-
secutive measurements in patients who had pre-
viously achieved complete viral suppression.
116 Italian Guidelines for the use of antiretroviral drugs and the diagnostic-clinical management of people with HIV-1 infection
→ Rank Virological efficacy Immunological
efficacy
Compactness/convenience
(number of pills and
administrations, co-formulation)
Extensive
clinical use
Genetic barrier (lower
frequency of resistance
at failure)
3 NVP*, DRV/r
RAL, LPV/r
DRV/r
RAL
4 FPV/r, SQV/r
*If administered QD, rank 2
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TABLE 10 - Recommendations for accurate, early assessment of virological failure.
Condition Recommendation
Patients with residual low-level viremia (1-49 co-
pies/mL).
Documentation of residual low-level viremia no longer satisfies the cri-
teria for diagnosis of virological failure. On the basis of the data availa-
ble there is no indication for modification of the current regimen [AIII].
Patients with viral blips (50-1000 copies/mL), iso-
lated, non consecutive, alternating with unde-
tectable viral load measurements.
Investigate adherence, potential pharmacological interactions, consider
possible variability in the HIV-RNA test. Modification of the antiretro-
viral regimen is not necessary [AII].
Patients with viral blips (50-1000 copies/mL) per-
sistent, consecutive, progressively rising, genoty-
pe non determinable.
There is no clear guidance in the literature on the appropriate manage-
ment of these patients, although active, persistent viral replication is evi-
dent. It is reasonable to undertake genotyping and consider modification
of the current antiretroviral regime [BII].
Patients with viremia >1000 copies/mL and ab-
sence of mutations in the genotypic resistance
test performed.
Investigate adherence, consider resumption of the same regimen moni-
toring the virological response after 4 weeks and repeating genotype for
early identification of emergence of resistant viral variants [BIII]. In pa-
tients on unboosted protease inhibitor therapy, consider immediate in-
troduction of low doses of ritonavir as a pharmacokinetic booster [BII].
Patients with viremia >1000 copies/mL and mu-
tations in the genotype test performed.
Modify the current antiretroviral regime [AII].
TABLE 11 - Useful considerations when deciding on a new antiretroviral regimen in patients 
with virological failure.
In a patient with virological failure, a new antiretroviral regimen must include at least 2, preferably 3 fully active drugs [AII].
In the case of first failure, it is advisable to choose drugs from classes that have not been used before.
With standard tests, the most recent genotype may not detect certain archived mutations. All of the patient’s previous ge-
notypic and phenotypic assays must be taken into consideration (when deciding on the appropriate choice of a new regi-
men); even agents to which the patients has never been exposed may not be fully active.
Consider all potential negative pharmacological interactions with the new regimen; a drug never taken before is not always
a fully active drug when included in a new therapeutic regimen.
In patients who do not have three fully active drugs available, consider that some antiretroviral drugs (e.g. NRTIs) can
contribute to the efficacy of the new regimen with partial antiviral activity, albeit in the presence of resistance, while for
other drugs (e.g.: enfuvirtide, NNRTIs, raltegravir) no partial antiviral activity has been demonstrated.
Certain factors are associated with a more favourable virological response, irrespective of the type of regimen used (e.g.:
low-level viremia and elevated CD4+ at the time of regimen modification, use of a drug from a new class, increasing num-
ber of active drugs and, therefore, GSS and PSS).
TABLE 12 - Recommended sequential regimens as determined by failed first line therapy.
First regimen Second regimen
2 NRTI + NNRTI 2 NRTI* + PI/r
2 NRTI + PI/r 2 NRTI* + PI/r*
2 NRTI + PI 2 NRTI* + PI/r*
3 NRTI *1 NRTI + 1 PI/r + 1 NNRTI
*2 NRTI + 1PI/r
1PI/r + 1 NNRTI - 1PI/r + 1 INI - 1 PI/r + 1 CCR5 inhibitor
* = Chosen on the basis of resistance assay.
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ADHERENCE AND QUALITY OF LIFE
Optimal adherence to antiretroviral drugs must
always be pursued in order to obtain and main-
tain both the viro-immunological and clinical suc-
cess of treatment [AII]. In the clinical setting, the
patient’s self-reported adherence, if investigated
with a non-judgemental, routinized and struc-
tured fashion, is the most suitable method to
measure adherence and institute longitudinal
monitoring for early identification of specific bar-
riers to adherence [AII]. Other objective meth-
ods, such as assessment of antiretroviral refill
dates, pill counts, and plasma drug concentration
monitoring may be utilized as adjunctive infor-
mation to assess patient adherence [BII].
Simplified antiretroviral dosing with fixed-dose
combinations has been shown to promote ad-
herence to the antiretroviral therapy [AI].
In the clinical setting, observation of non-adher-
ence behaviour requires intervention strategies
[AI]. Identification of the most appropriate in-
tervention is based on the experience of the med-
ical-nursing staff and is based on a “tailored” ap-
proach combining strategies related to the anti-
retroviral management with educational and be-
havioural approaches providing support to the
patient [BI]. The improvement in quality of life
related to health is a primary objective of anti-
retroviral therapy. It is therefore necessary to in-
clude the use of patient-centered strategies in the
clinical care of the patient. Ongoing monitoring
of patient-centered outcomes is recommended in
clinical centres, with the same frequency as stan-
dard clinical examinations [AII].
PHARMACOLOGICAL MONITORING
Definition of TDM
Therapeutic monitoring of plasma drug concen-
trations (TDM - Therapeutic Drug Monitoring) is
a useful adjunct for individualizing therapy, es-
pecially when utilzing agents with a clear corre-
lation between concentration and therapeutic
and/or toxic effect, a limited therapeutic margin
and wide inter-individual pharmacokinetic vari-
ability.
TABLE 13 - Management of virological failures subsequent to the first and use of new classes of drugs.
Situation Choice
Availability of at least 2 active drugs* Change the regimen as soon as possible. If possible include high genetic barrier
drugs in the regimes (new boosted protease inhibitors) in combination with other
agents of different classes chosen on the basis of resistance test results.
Availability of 1 active drug only* The most fragile situation, the decision to modify antiretroviral therapy must take
into account the immediate risk of clinical progression, the risks associated to main-
tenance of the current regimen and the probability of virological success of the sub-
sequent regime in the medium term. A maintenance regimen may be reasonable whi-
le awaiting the availability of another active drug.
Absence of active drugs Determine the optimal maintenance regimen.
*of all agents available, in the market or in early access protocols.
TABLE 14 - Clinical scenarios of possible use of TDM.
Scenario Strength/evidence
Significant alterations of gastroenteric, hepatic or renal function [CIII]
Pregnancy LPV/r, SQV/r [CIII]
Previous failures with resistant virus PI with use of IQ [CII]
Concentration-correlated toxicity IDV/r [BII], EFV [CII], ATV [CIII]
Non-conventional dosing schemes [CIII]
Treatment adherence [CIII]
Pharmacological interactions [BIII]
Interactions
The management of pharmacological interactions
is the clearest clinical indication for use of TDM
[BIII]. Different antiretroviral drug types or class-
es (NNRTI, IP, MVC) are associated with signifi-
cant pharmacological interaction as they are, to
various extents, substrates, inhibitors or induc-
ers of the P450 cytochrome (in particular the
CYP3A4 isoenzyme, but also CYP2B6, CYP2C9,
CYP2C19) and P glycoprotein. The N(t)RTI, ENF
and RAL have differentiated metabolic profiles
and therefore have limited or low potential for
interaction. Refer to specific sites (first of all
www-hiv-druginteractions.org) for an exhaus-
tive discussion of information pertaining to man-
agement of pharmacological interactions.
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PHARMACO-GENETICS
TABLE 15 - Principles of TDM use in the
management of pharmacological interactions.
NNRTI, PI and MVC have a higher risk of pharmacologi-
cal interaction as substrates, inhibitors or inducers of the
P450 cytochrome system and P glycoprotein.
N(t)RTI, ENF and RAL have limited or low potential for in-
teraction.
The extent of a known interaction may be unpredictable
in individual cases [CIII].
The sum of several simultaneous pharmacological inte-
ractions is often difficult to predict [CIII].
The extent of the interaction may have different specific
weights and effects depending on the clinical variables of
the single case [CIII].
A pharmacological interaction may be unpredictable and
must be suspected in the case of unexpected clinical and
therapeutic events [CIII].
TABLE 16 - Principles of use of genetic testing 
for the HLA-B*5701 allele.
Highly recommended before starting antiretroviral the-
rapy containing ABC [AI].
In negative patients clinical monitoring is recommended
in all cases within the first 6 weeks of treatment as the
possibility of abacavir associated HSR cannot be com-
pletely excluded [CIII].
The test should be performed at baseline in all newly in-
fected patients in order to register data in the patients’
clinical records for future use [CIII].
NON-INFECTIOUS COMORBIDITY
General principles
The non-infectious pathologies associated with
HIV infection are the most frequent symptomatic
manifestations in HIV-infected persons on anti-
retroviral therapy. 
These derive from the interaction of risk factors
relative to host, virus, and drug [BII]. Their clin-
ical relevance affects:
- prognosis [AI];
- choice or modification of the antiretroviral
drugs [AII];
- multidisciplinary patient management [AIII].
These comorbidities manifest in progressive or-
gan damage leading to end-stage organ failure:
- End-stage organ failure determines patient
morbidity and mortality [BII].
- They may be diagnosed by functional or struc-
tural tests with the capacity to detect disease in
the asymptomatic stage [BII].
- Multiple comorbidites are physiological during
aging and HIV infection is associated with a
process of premature aging the pathogenetic
mechanisms of which are only partially under-
stood.
Risk factors associated with HIV infection are re-
lated to genetic and environmental factors which,
in turn, affect lifestyle. 
The recognition and correction of deleterious
lifestyle choices are the most effective interven-
tions for prevention and treatment of non-infec-
tious comorbidities. 
Factors related to HIV infection include im-
munological damage (immunodeficit and im-
mune deregulation) and by a state of systemic in-
flammation associated with accelerated the cel-
lular and organ senescence. 
Undetectable HIV viremia does not eliminate
the excess risk associated with HIV disease. Co-
infections (hepatitis viruses, herpes viruses,
etc.) are additional risks for non-infectious
pathology. 
The increased risk of specific organ damage as-
sociated with cumulative or current antiretrovi-
ral exposure occurs through mechanisms which
have not been fully elucidated.
The table below shows the main risk factors for
non-infectious comorbidites associated with HIV
infection considered in these guidelines [AIII].
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Screening for non-infectious comorbidities as-
sociated with HIV infection
Screening for non-infectious comobidities is an
integral part of comprehensive clinical assess-
ment in all HIV infected patients [AII]. Screening
must be periodic and should be repeated, in all
patients, before starting antiretroviral therapy or
when changing antiretroviral management strat-
egy [AIII].
→
TABLE 17 - Risk factors for non-infectious comorbidities associated with HIV infection.
Heart Kidney Bone Liver Cancers Lipodystrophy
Age 4 4 4 4 4 4
Sex 4 4 4 4
Diabetes 4 4 4 4 4
Hypertension 4 4
Dyslipidaemia 4 4 4 4 4
Family history 4 4 4 4
Waist circumference 4 4 4
Vit D/PTH 4 4 4 4 4 4
Smoking 4 4 4 4 4 4
CD4+ 4 4 4
HIV VL 4 4
ARV 4 4 4 4 4 4
TABLE 18 - Screening strategies for non-infectious comorbidities associated with HIV infection.
Assessment At HIV
diagnosis
Before start 
of cart
Follow-up freq.
with cart
Follow-up freq.
without cart
Comments
Anamnesis
Prior and current
non-infectious
pathologies.
+ + Assessment to be repea-
ted if patient transferred
to other care centre
Family history
(e.g. early
cardiovascular
disease: indicates
cardiovascular
events, diabetes,
hypertension,
chronic kidney
disease)
+ + Early cardiovascular dis-
ease - cardiovascular
events in first degree fa-
mily members: males <55
years, females <65 years
Concomitant
pharmacological
therapies
+ + at each visit at each visit
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Assessment At HIV
diagnosis
Before start 
of cart
Follow-up freq.
with cart
Follow-up freq.
without cart
Comments
Anamnesis
Current lifestyle:
- alcohol
consumption
(toxic alcohol
damage is
expressed in
consumption
exceeding 30
grams/day in
males and 20
grams in females)
- smoking
- diet
- physical activity
+ + Every 6-12
months
once a year More frequent discussion
with the patient of healthy
lifestyle and habits is re-
commended
Body
composi-
tion
Measurement of
body mass index
and waist
circumference
+ + once a year once a year Objective examination for
lipodystrophy must be
segmental, where possible
using assessment me-
thods for the diagnosis of
the lipo-atrophy and lipo-
hypertrophy.
The objective tools for of
measurement of lipo-
atrophy and lipo-hyper-
trophy include DEXA
(with measurement of the
fat mass in the limbs), ab-
domen CT (with measu-
rement of visceral subcu-
taneous fat) and ultraso-
nography assessment of
the depth of subcuta-
neous fat in the limbs and
cheeks [BIII]
Clinical
assessment of
lipodystrophy
+ + once a year once a year
Cardio-
vascular
disease
Assessment of
overall risk
+ + once a year once a year Using algorithms such as
Framingham (http://
hp2010.nhlbihin.net/at-
piii/CALCULATOR.asp?u
sertype=prof), PROCAM
(http://www.chd-taskfor-
ce.com/procam_interacti-
ve.html), Raynolds (http://
www.reynoldsriskscore.or
g), SHAPE (http://www.
shapesociety.org/your_le-
vels_of_risk/) and in per-
sonal clinical evaluation
ECG +
Hyperten-
sion
Blood pressure + + once a year once a year
Dyslipidae
mia
TC, HDL Col,
LDL Col, TG
+ + once a year
→
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→ Assessment At HIV
diagnosis
Before start 
of cart
Follow-up freq.
with cart
Follow-up freq.
without cart
Comments
Diabetes
mellitus
Serum glucose + + Every 6-12
months
Consider oral glucose
load test if fasting glycae-
mia values rare repea-
tedly between 110-125
mg/dl
Liver
disease
Risk assessment,
ALT/AST, GGT
+ + Every 3-6
months
Every 6-12
months
Frequency of checks must
increase before and du-
ring treatment with hepa-
totoxic drugsLiver
ultrasonography
in patients with
liver enzyme
elevation
+ + once a year once a year
Kidney
disease
Risk assessment + + once a year once a year
eGFR estimated
possibly with the
CKD-EPI
calculator or
alternatively
MDRD or
Cockroft-Gault
+ + Every 3-6
months
Every 6-12
months
Frequency of checks must
increase in the presence
of risk factors for chronic
kidney disease and/or be-
fore and during treatment
with nephrotoxic agents
Urinalysis for
proteinuria and
plasma phosphate
levels 
+ + once a year once a year Every 6 months with esti-
mated eGFR <60 ml/min;
with proteinuria ≥1 +
and/or estimated eGFR
<60 ml/min, measure pro-
tein/creatinine in urine.
In patients starting a te-
nofovir-containing regi-
men the initial asses-
sment including plasma
phosphate level must be
conducted after 2-4 weeks
and every 3-6 months the-
reafter
Bone
disease
Height
measurement
+ + every 2 years every 2 years In the case of a loss of
more than 3cm in height,
lateral spine Xrays (tho-
racic) are indicated [AII]
Assessment of
major risk factors
for osteoporosis
+ + once a year once a year
Estimate of risk
of fractures in
subjects aged >40
years with FRAX®
+ + Every year every year
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→ Assessment At HIV
diagnosis
Before start 
of cart
Follow-up freq.
with cart
Follow-up freq.
without cart
Comments
Bone
disease
Vitamin D dosage + twice a year twice a year Preferably to be perfor-
med in the autumn and
spring, not necessary if
nutritional supplementa-
tion given [AII]
Examination of
bone mineral
metabolism (at
least 1 re-
absorption
marker and 1
deposit marker)
and PTH
+ Every year Every year [AII]
DXA scan of the
lumbar spine and
hip or
densitometry
surrogate tests
+ every 2 years every 2 years DXA is indicated when, in
addition to HIV, at least 2
of the following risk fac-
tors are present: hypogo-
nadism, family history of
fractures, BMI <19 kg/m2,
hypovitaminosis D, smo-
king, sedentary lifestyle,
history of low impact
fractures, advanced age,
female sex, menopause
and/or amenorrhea, habi-
tual alcohol excess (>3
units/ day), steroids expo-
sure for >3 months [BIII].
DXA has the advantage of
providing objective anth-
ropometric measure-
ments for the diagnosis of
lipodystrophy [BIII]
Assessment of the risk of toxicity associated
with antiretroviral drugs
There are short- and medium-term toxicities
linked with the use of antiretroviral drugs.
Continuous exposure to antiretroviral therapy re-
inforces the need for post-marketing pharmaco-
logical surveillance [BII]. 
HIV infection control through virological sup-
pression is a required for reducing drug related
toxicities [AI].
The principal toxicities attributable to different
classes and single drugs, based on data from reg-
istration studies or significant cohort studies, are
listed below.
TABLE 19 - Principal toxicities attributable to different ARV classes and single drugs.
Rash -
hypersensi-
tivity
Gastroin-
testinal
Hepatic to-
xicity
Cardiovas-
cular
Bone/mu-
scle
Renal 
toxicity
Nervous
system
Lipody-
strophy
Metabolic
alterations
NRTI X X X
AZT X X X X X X
d4T X X X X X
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Rash -
hypersensi-
tivity
Gastroin-
testinal
Hepatic to-
xicity
Cardiovas-
cular
Bone/mu-
scle
Renal 
toxicity
Nervous
system
Lipody-
strophy
Metabolic
alterations
ddI X X X X X
3TC
FTC
ABC X X X
TDF X X
NNRTI X
EFV X X X X
NVP X X
ETV X
PI X X X X X
IDV X X X X X X
SQV X
LPV X X X
FPV X X X X
ATV X X
DRV X
TPV X X X
Fusion 
inhibitors
ENF X
Integrase
inhibitors
RAL X X
CCR5
Inhibitors
MVC X
→
General principles of treatment of non-infectious comorbidities
TABLE 20 - Principles of intervention for main modifiable factors.
Interventions Principles
Smoking cessation Identify the motivational aspects for discontinuing smoking
The short-term benefits are:
- monetary savings
- increased perception of flavours
- improved skin trophism
- reduction of dyspnea.
→
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TABLE 21 - Identification and management of patients at high risk of cardiovascular disease.
Identification of patients with high cardiovascular risk through:
1. Estimation of the risk of cardiovascular disease (CVD) with risk prediction charts or algorithms
2. Individual clinical assessment
Advise on diet and lifestyle in all patients
Consider individualized modification of ARV therapy in patients with high CV risk
Identification of modifiable risk factors
Smoking Blood pressure Coagulation Glucose Lipids
Start treatment if: systolic
blood pressure (SBP) ≥140
or diastolic blood pressure
(DBP) ≥90 mmHg
(especially if 10-year CVD
risk ≥20%)
Start
treatment if:
CVD present
or age ≥50
and 10-year
risk ≥20%
Confirm
diagnosis of DM
and start
therapy if:
HBA1c ≥6.5%
Start treatment therapy if: CVD present or
type II DM II or TC:HDL ratio >6 or 
10-year risk ≥20%
Target Target - N/A Target HBA1c
<6.5%
Target
If DM or
CVD or
CKD+protei
nuria. BP
<130/<80
Absence of
DM and
CVD, BP
<140/<90
Treatment
with
acetylsalicylic
acid 
75-150 mg/d
Optimal Standard
TC 155 mg/dL 190 mg/dL
LDL 80 mg/dL 115 mg/dL
Interventions Principles
Smoking cessation The long-term benefits are:
- prevention of chronic obstructive pulmonary disease (COPD)
- coronary artery disease and stroke
- lung cancer
Instruments of proven utility for smoking cessation:
- refer to specialist anti-smoking centres
- nicotine substitute products
Diet Nutritional counselling:
- Maintain the balance between calorie input and energy consumption
- Moderate intake of saturated fats, cholesterol and refined carbohydrates
- Limit alcohol consumption to <20 gr/day for females and <30 gr/day for males
- Reduce total fat intake to <30% and cholesterol intake to <300 mg/day
- Consume many vegetables, fruit and fibre rich cereals
- Introduce fish, poultry (no skin) and lean meat to the diet
- Avoid alternating periods of strict diet and binges (so-called yo-yo dieting)
Specialist nutritional intervention reserved for obese patients and those with wasting syndrome
Physical therapy An active lifestyle is fundamental to prevent and treat obesity, hypertension and diabetes.
Regular aerobic activity (e.g. 30 minutes of sustained walking at least 5 days a week) is useful to
reduce the accumulation of visceral fat, maintain muscular strength and prevent osteoporosis.
It is necessary to verify that the physical activity undertaken satisfies cardio-fitness requirements
(adequate duration, adequate increment of cardiac frequency)
→
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Prevention and management of patients at high risk of hepatic damage
Prevention Management
In the case of co-infection with Hepatitis C virus evaluate
the possibility of treating this condition: treatment of
Hepatitis C reduces the risk of “drug-induced liver injury”
(DILI). Refer to the specific section of the guidelines for ma-
nagement of these cases.
In obese patients and those with metabolic syndrome, ul-
trasonography to assess the presence of NAFLD. Computed
tomography (CT) and magnetic resonance imaging (MRI)
may be used for further diagnostics in selected cases.
Modifying predisposing factors for NAFLD such as hypergly-
caemia, dyslipidaemia, arterial hypertension, abdominal obe-
sity, may reduce the evolution of liver disease and prevent
drug-related hepatotoxicity. Among the modifiable predi-
sposing factors consider HCV infection with genotype 3,
which is associated with hepatic steatosis and an increased
risk of drug-associated liver damage.
In patients starting nevirapine: check liver enzymes at base-
line, every two weeks for the first month, each month for the
first three months, then every three months.
Reassessment of current antiretroviral therapy: because li-
ver damage - above all when linked with mitochondrial to-
xicity - may be clinically silent, it is important to evaluate
the possibility of substituting older generation NRTI if pre-
sent in current therapy.
Exclude other causes of liver enzyme elevation, in particular
alcohol abuse, presence of co-infections with hepatitis viru-
ses and interruption of treatment with 3TC, FTC and TDF
in patients with chronic hepatitis B.
In the case of liver enzyme elevation, if the patient is sympto-
matic with a clinical hepatitis or a concomitant rise in bili-
rubin, immediately discontinue all current treatment. Upon
normalization, consider the use of antiretroviral drugs with
minimal hepatic toxicity.
In the asymptomatic patient, consider suspension of the drug
in all patients with liver enzyme elevation 5-10 times the nor-
mal level.
In the presence of both augmented liver enzyme elevation
and of symptoms drug hypersensitivity reaction, suspend
current treatment immediately. Re-administration of the sa-
me therapy may prove fatal.
Prevention and management of patients at high risk of bone disease
Prevention Management
Lifestyles beneficial for the prevention and treatment of
osteoporosis include: physical activity, daily consumption of
1 g of calcium and Vit D 800 UI/day with a weight loss and
malabsorption prevention diet (BMI <18.5), smoking cessa-
tion and decreased alcohol consumption. A height loss of
more than 3 cm suggests a diagnosis of vertebral fracture.
The classic risk factors for osteoporosis include: hypogona-
dism, family history of fractures, BMI <19 kg/m2, hypovita-
minosis D, smoking, sedentary lifestyle, low impact fractures,
advanced age, female gender, menopause and/or amenor-
rhea, habitual alcohol consumption of >3 units/day, steroids
exposure for >3 months.
Plasma levels of 25-OH vitamin D should be checked in all
patients preferably in autumn and spring. Testing is not ne-
cessary in patients taking regular nutritional supplementa-
tion. Correct assessment of the bone structure cannot be se-
parated from a study mineral metabolism.
The bone toxicity of tenofovir is expressed in particular in
the first 12 months of therapy, especially if used in associa-
tion with PI/r and in pre-treated subjects: in the case of alte-
rations in renal function and/or of bone metabolism, and in
the presence of valid, efficacious alternatives, it is advisable
to assess options for treatment modification.
There are no antiretroviral therapy simplification strategies
of proven efficacy in the prevention or treatment of osteo-
porosis. For correction of hypovitaminosis D, cholecalciferol
must be administered: two consecutive oral administrations
of 300,000 UI each, preferably in spring and autumn, follo-
wed by a maintenance dose of oral cholecalciferol of 7,000
UI each week.
In the case of hypovitaminosis, testing of plasma calcium,
phosphate, alkaline phosphatase and PTH levels is indica-
ted. Always supplement with calcium in the case of low ali-
mentary intake.
Prevention and management of patients at high risk of lipodystrophy
Prevention Management
For all patients with HIV infection, collection of anthropo-
metric data including BMI, waist circumference, objective
evaluation of adipose tissue redistribution is indicated, pos-
sibly with questionnaires.
Modification of antiretroviral therapy, replacing thymidine
analogues, is the only measure proven to partially re-esta-
blish subcutaneous fat, with an average increase in total fat
in the limbs of up to 400-500 g/year. The option of NRTI-spa-
ring regimes is also available.
→
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Prevention Management
A correct diet and physical activity can reduce the accumu-
lation of visceral fat and lead to improvement in insulin sen-
sitivity and blood lipids, especially in obesity associated with
lipo-hypertrophy. This intervention may, however, exacerba-
te subcutaneous lipo-atrophy.
Replace d4T or ZDV with abacavir (ABC) or tenofovir (TDF).
The potential risk of toxicity linked with the use of these
drugs must be taken into consideration.
Avoid use of stavudine (d4T) and of zidovudine (ZDV, AZT),
or switch to other drugs as prevention.
Consider Nucleoside Reverse Transcriptase Inhibitors
(NRTI)-sparing regimens. Using these regimes may be asso-
ciated with an increase risk of dyslipidaemia.
There are no antiretroviral therapy switch strategies with
proven efficacy in the treatment of lipo-hypertrophy.
Surgical intervention to correct facial lipo-atrophy is not ae-
sthetic surgery but repair of an iatrogenic injury. Indeed, the-
se have a positive effect on the quality of life and on depres-
sion, reducing the stigma of HIV disclosure and infection
“revealed” by recognition of the lipo-dystrophic phenome-
non, and is a potential intervention to support adherence to
antiretroviral therapy.
The surgical approach may be undertaken either by auto-
transplant of adipose tissue (lipo-filling) or by treatment with
synthetic fillers (re-absorbable or not), in patients without
adipose tissue for use as a donor site [BI]. The re-absorbable
synthetic fillers are preferable in patients with less severe li-
po-atrophy and under 50 years of age, while non re-absor-
bable synthetic fillers are preferred in cases of more severe
lipo-atrophy in those over 50 years old [BIII]. The use of
synthetic fillers is not recommended in the treatment of non
facial lipo-atrophy.
The use of medical therapies to improve lipo-atrophy has
produced conflicting results. In particular, the use of thiazo-
lidinediones such as rosiglitazone and pioglitazone did not
result in a significant increase of adipose tissue. Use of rosi-
glitazone can cause blood lipid elevations and an increased
risk of coronary heart disease.
Several drugs have been used to treat lipo-hypertrophy.
Growth hormone reduces visceral adipose tissue but may
exacerbate subcutaneous lipo-atrophy and insulin resistan-
ce. Tesamorelin (growth hormone release factor), currently
not authorized in Europe, has been shown to be efficacious
in reducing the volume of visceral adipose tissue. Metformin
reduces visceral adipose tissue in insulin resistant patients
but may exacerbate subcutaneous lipo-atrophy.
Surgical intervention to correct lipo-hypertrophy may be con-
sidered for removal of localised lipomas and to correct buf-
falo hump although the duration of the effect is variable
[BIII].
→
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Prevention and management of patients at high risk of kidney disease
Prevention Management
Assessment of glomerular function is performed with pre-
diction algorithms which include serum creatinine level, age,
sex, ethnic origin and anthropometric measurements.
Calculation of creatinine clearance is necessary, as the se-
rum creatinine value depends to a variable extent on extra-
renal factors; further, the correlation between creatinine and
glomerular filtratation is not linear. 
In cases of Fanconi syndrome in tenofovir-treated patients,
tenofovir must be discontinued immediately. In patients with
estimated glomerular filtrate <50 mL/min dose adjustments
should be performed where necessary.
The need for treatment modification should be assessed every
time GFR is below 60 ml/min and/or in the case of observa-
tion of proteinuria/ microhematuria.
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Prevention Management
Measurement urine over 24 hours, while more tim-consu-
ming, is more accurate and certainly preferable to use of the
Modification of Diet in Renal Disease (MDRD), Cockcroft-
Gault (CG), EPI-CKD formulae.
Given the close connection between renal damage and car-
diac damage, cardiovascular prevention interventions, with
particular reference to hypertensive disease, appear effica-
cious in the prevention of kidney disease as well.
In these cases, risk assessment for renal dysfunction is indi-
cated, discontinue or change drug doses where indicated,
and consider ultrasonography of the kidneys; in the case of
hematuria, irrespective of the degree of proteinuria, consult
a specialist nephrologist.
→
SCREENING AND INVESTIGATIONS FOR PROTEINURIA
 
Urine test for proteins (Dipstick)
+ -
- Proteinuria 
  < 300 mg/24 h
- µP/Cr < 0,3 mg/mg
- No alteration
- Proteinuria >300 mg/24 h
- µP/Cr <0,3 mg/mg e/Hematuria
or abnormal ultrasound
or estimated GFR < 60 mL/min
 
- Annual renal screening
- Nephrological consultant
- Renal biopsy 
Always consider:
- Hypertension
- Diabetes
- Metabolic syndrome
- HIVAN
- Effects of the drugs
• Urine protein/creatinine ratio (µP/Cr), 
 or proteinuria 24 h
• Renal ultrasonography
• Estimated GFR (and GFR)
Routine clinical follow-up
If <90 mL/min 
or proteinuria positive
If normal 
or GFR stable 
>60 mL/min
 
If:
- Proteinuria, glycosuria
- Hematuria
- Hypophosphatemia
- ultrasound alterations
- eGFR <60 ml/min
If >90 mL/min:
SCREENING AND SEARCH FOR IR with eGFR
Measure serum creatinine and proteinuria upon Þnding clinical HIV
Calculate eGFR (preferably with CKD-EPI algorithm)
Standard urine test for proteinuria/glycosuria/hematuria
- Renal ultrasonography
- Phosphoremia
- Proteinuria
- A.P. measurement
- Exclude diabetes
- Renal ultrasonography
Always consider:
- Hypertension
- Diabetes
- Metabolic syndrome
- HIVAN
- Effects of the drugsAnnual renal screening Nephrological consultant
FIGURE 1 - Clinical management of renal failure (1a) and proteinuria (1b).
1a
1b
HIV-associated neuro-cognitive disorders
The clinical outcome and quality of life of peo-
ple with HIV infection can be profoundly influ-
enced by the presence of neuro-cognitive and/or
psychiatric disorders, whether these are the con-
sequence of HIV damage to the central nervous
system (CNS) - defined in this case as HIV-asso-
ciated neuro-cognitive disorders (HAND) , attrib-
utable to other causes, or to the combination of
the two.
HIV does not infect neurons directly, but the in-
fection and consequent activation of CNS
macrophages, the target cells in this tissue, can
trigger a cascade of events, including the pro-
duction of inflammatory, neurotoxic molecules
leading to neuron dysfunction, degeneration and
death. 
The clinical equivalent of these events is repre-
sented by a neurocognitive disorder which, in
more severe forms, manifests with a state of de-
mentia (HAD, HIV-associated dementia). A clas-
sification of HAND was recently proposed on the
basis of the severity of the deficit, as established
by neuropsychological examination. 
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TABLE 22 - Classification of HIV-associated neurocognitive disorders (HAND).
Alteration in ≥2 cognitive areas
documented by np exam
Interference with daily life
Asymptomatic Neurocognitive
Impairment (ANI)
Present No
Mild Neurocognitive Deficit (MND) Present Mild
HIV-associated dementia (HAD) Present Severe
HAND: HIV-associated - Disorders; ANI: Asymptomatic Neurocognitive Impairment; MND: Mild Neurocognitive Disorder; HAD: HIV-Associated Dementia;
NP Exam: Neuropsychological Examination
While the incidence of HAD fell after the intro-
duction of combination antiretroviral therapy
(cART), the general prevalence of neuro-cogni-
tive disorders rose, likely due the increase over
time of incident cases and the longer survival of
HIV-infected individuals, and now affects 25%-
50% of patients. HAND is associated with sever-
al risk factors, including:
- A CD4+ nadir <200 cells/µL;
- Age over 50 years;
- Co-infection with HCV, diabetes or insulin re-
sistance.
HIV-infected patients have a high prevalence of a
number of conditions/comorbidities that are in-
dependently associated with neurocognitive dis-
orders which may contribute to or totally explain
the cognitive deficit, and confound a diagnosis of
HAND:
- Depression;
- Anxiety disturbances;
- Psychoses and other psychiatric disorders;
- Vascular and ischemic dementia;
- Alzheimer’s disease;
- Opportunistic infections or CNS neoplasia;
- Metabolic encephalopathies;
- Hepatic cirrhosis;
- Co-infection with HCV;
- Current or previous history of drug abuse (co-
caine, methamphetamine, opiates);
- Abuse of psychiatric drugs;
- Alcoholism;
- Prior concussive cranial trauma.
Diagnosis of HIV-associated neurocognitive
disorders (HAND)
The diagnostic procedures recommended for the
management of the patient with or at risk of
HAND are reported below.
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12 months
Normal
Repeat IHDS/
MMSE after 
12 months
Repeat NP/ IADL
exam after 
12 months
If aimed anamnesis suspected, 
effect screening for psychiatric 
disorders3
FIGURE 2 -Diagnostic algorithm for the diagnosis and treatment of HIV-associated neurocognitive disorders (HAND).
Abbreviation legend - IHDS: International HIV Dementia Scale; MMSE: Mini Mental State Examination; IADL: Instrumental
Activities of Daily Living; NP Exam: Neuropsychological Examination; MRI: Magnetic Resonance Imaging of the brain with con-
trast media. Notes on the algorithm: 1To highlight difficulties in the execution of one or more of the following functions: plan
and execute complex tasks; perform simple, timed, cognitive functions; maintain usual levels of attention; have good tempo-
ral-spatial orientation; maintain behaviour suitable to environmental circumstances; have good prospective memory or mem-
ory of activities or future plans; and to highlight shades of possible psychiatric symptomatology (e.g. symptoms of depression
or anxiety). 2Patients with evident and/or documented neurocognitive alterations do not require screening tests and are direct
candidates for NP exam. To enhance the diagnostic sensitivity of the MMSE some experts propose raising the classic cut-off
from 24/30 to 28/30. 3In patients with symptoms not explained by neurocognitive alterations, specialist consultation is indicated
for the diagnosis and treatment of possible psychiatric or psychological disorders. 4Include neurological examination and blood
tests to exclude conditions/co-morbidities associated with non-HAND neuro-cognitive disorders. 5Risk factors: CD4+ nadir
<200 cells/µL, age >50 years, HCV-Ab positivity, diabetes or insulin resistance. 6Examinations aims to distinguish HAND and
exclude other pathologies. The CSF test is indicated principally to study HIV-RNA level (concomitant with evaluation of plas-
ma viremia) and of drug resistance. 7To define drugs with elevated penetration and efficacy in the CNS, the use of Central nerv-
ous system Penetration Effectiveness - CPE Score (Letendre S et al., CROI 2010) is recommended [see below].
Italian Guidelines for the use of antiretroviral drugs and the diagnostic-clinical management of people with HIV-1 infection 131
TABLE 23 - Diagnostic route to diagnosis of HIV associated neurocognitive disorders (HAND).
Level Examination(S) Objective(S) Population
1a Targeted history-taking*,
neurological examination
Identification of patients with possible
neurocognitive or psychiatric disorders
All [AIII]
1b IHDS, MMSE Identification of patients with possible
neurocognitive disorders.
All [AIII] or, where not practicable in all, at
least in patients with 1 or more risk factors
(Figure 1, note 5)
2a Neuropsychological exami-
nation
Diagnosis of neurocognitive impair-
ment and definition of severity.
Patients with suggestive clinical history [AII];
patients with IHDS ≤10 [AII] or MMSE
<28** [BII]
2b IADL questionnaire Evaluation of functional impact
Diagnosis of HAND severity
Patients with altered NP exam [AII]
2c Specific questionnaire Screening for depression and other
psychiatric disorders
Patients with symptoms emerging at anam-
nesis, but NP exam within the norm [AII]
2d Laboratory and instrumen-
tal tests
Exclude confounding disorders Patients with altered NP exam [AII]
3a Neurological examination Exclude confounding disorders
Diagnosis of HAND severity
Patients with altered NP exam [AII]
3b MRI of the brain Exclude confounding disorders
Search for HAND compatible signs 
Patients with HAD or MND [AII]
Patients with ANI and ≥2 risk factors [BII]
3c Examination of cerebro-
spinal fluid (CSF) specimen 
Exclude confounding disorders
HIV-RNA, GRT 
Patients with HAD [AII] or MND [BII]
Patients with ANI and ≥2 risk factors [BII]
GRT: Genotypic Resistance Test. *See note 1 above. **See note 2 above.
TABLE 24 - Antiretroviral therapy in patients with mild neuro-cognitive disorders (MND) 
or HIV-associated dementia (HAD).
Clinical scenario and possible biological basis ARV Therapy*
Not on ARV
therapy,
MND/HAD 
Productive infection of CNS ARV therapy with 3 drugs, all with elevated pene-
tration and efficacy in the CNS, also taking into ac-
count GRT in plasma and, if available, in CSF [AII] 
On ARV
therapy
with
therapeutic
failure,
MND/HAD
a) HIV RNA detectable in CSF with GRT comparable
or different to plasma: productive infection of CNS
due to to high viral replication in the CNS and/or re-
sistance in the CNS and/or poor penetration/ efficacy
of ART in CNS.
b) HIV-RNA not detectable in CSF: possible low-level
HIV replication in CSF or presence of chronic CNS
damage
Modification of ARV therapy on the basis of the GRT
on plasma (a, b) and on CSF (a), using more effec-
tive or at least equivalent o current therapy in terms
of CNS penetration and efficacy.
On ARV
therapy
with
viremia
suppressed,
MND/HAD
a) HIV-RNA detectable in CSF: productive infection
of CNS due to compartmentalised viral replication
and/or resistance in CSF and/or poor penetration/ ef-
ficacy of ART in CNS.
b) HIV-RNA not measurable in CSF: possible low-level
HIV replication or presence of chronic damage to CNS.
Modification of ARV therapy on the basis of the GRT
on CSF and previous resistance tests on plasma, with
preference for agents with elevated CNS penetration
and efficacy (a) [AII]. Strengthening therapy by ad-
dition of one or more drugs with elevated CNS pe-
netration and efficacy (a, b) [BIII].
*For drugs with elevated CNS penetration and efficacy, refer to Table 3 on the CPE score (see full version of the Guidelines), in which the drugs with most
elevated penetration and efficacy are assigned a higher score.
Prevention of symptomatic HIV-associated
neuro-cognitive disorders (HAND) (MND,
HAD)
In the absence of MND or HAD it is important to
identify the patients most at risk of developing
symptomatic neuro-cognitive impairment in the
future and to employ effective strategies for its’
prevention. 
In both patients with ANI, and patients without
neuro-cognitive alterations, but with risk factors
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(CD4+ nadir <200 cells/µL, age >50 years, co-in-
fection with HCV, diabetes or insulin resistance),
careful neuro-cognitive monitoring is indicated
(with NP and IADL exam every 12 months to eval-
uate eventual evolution towards MND) [AII]; the
use of drugs with elevated CNS penetration and
efficacy both in cases of with ≥2 risk factors for
HAND development [AII], and in patients with
no compromise and ≥2 risk factors is suggest-
ed[CIII].
TABLE 25 - Monitoring the efficacy of antiretroviral therapy in HIV-Associated neuro-cognitive disorders
(HAND).
Level Scenario Objective Examinations
1 Starting or changing cART, HAND Initial evaluation of the efficacy of
the (new) therapy on the neuro-co-
gnitive impairment
After 6 months: NP exam [AII] 
2° cART monitoring: HAND with reco-
very of neuro-cognitive impairment
Monitor the efficacy of cART on the
neuro-cognitive impairment
Every 12 months: NP exam [AII] 
2b cART monitoring: HAND with no re-
covery or worsening of neuro-cogni-
tive impairment 
Search for virological escape in the
CNS
Exclusion of other causes of neuro-
cognitive impairment
Neurological examination [AII]
MRI of the brain [AII]
CSF examination (HAD and MND)
and tests to exclude other disor-
ders [AII], HIV RNA [AII], GRT
[AII]
After 6 months: NP exam [AII]
Tumours
Treatment for HIV-associated tumours is very
complex and must be the product of a strategic
and operative agreement between the oncologist
and the infectious disease specialist. 
This section is intended to focus only on certain
aspects of this complex problem, mainly ad-
dressing the general principles of timing, choice
and management of antiretroviral therapy in the
HIV patient with malignancies. 
Thus, this discussion must not be considered an
exhaustive review of the complex issue of tumour
management in the HIV-infected patient, a sce-
nario which requires specific study and recom-
mendations in clinical, diagnostic and therapeu-
tic domains.
HIV-positive patients must regularly undergo
screening for solid cancers, in particular for
breast cancer, colorectal neoplasia and prostate
carcinoma, whose cost-efficacy is largely docu-
mented in the general population [AI].
Initiation of HAART is, in general, recommended
concomitant to the anti-neoplastic treatment
[AII], with the possible exception of patients with
non-AIDS defining cancers, elevated CD4+ levels,
and possible drug interactions associated with se-
vere with toxicity [BIII]. HAART is recommend-
ed in all patients treated with highly immuno-
suppressive therapies.
In candidate patients for concomitant treatment
with HAART and chemotherapy (CT), considera-
tion of possible drug-drug interactions and cu-
mulative toxicity must guide and orient the
choice of antiretroviral therapy.
The potential interactions between antiretrovi-
rals and chemotherapy should be considered be-
fore the a therapeutic regimen is chosen [AIII],
with reference to the most up to date data in the
literature (see http://www.hiv-druginteractions.
org). 
The use of antiretroviral TDM is recommended to
check for interactions and accumulated toxicities
[CIII].
INFECTIVE COMORBIDITY
Infection by hepatitis viruses
When to start antiretroviral therapy
Patients with hepatitis virus co-infection -
Maintenance of CD4+ count over 500 cells/mL and
HIV viral suppression are recommended [BII].
Patients with HCV co-infection - With a CD4+
count >500 cells/µl, starting antiretroviral thera-
py is highly recommended [AII]. In patients with
indications for anti-HCV therapy with interferon
and ribavirin and with CD4+ <500 cells/mL or
with unstable HIV disease (indicated by HIV-RNA
>100.000 copies/mL and/or decline of the CD4+
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>100 cells/L in the last year) anti-HCV therapy
should be preceded by the initiation of antiretro-
viral therapy[AIII].
Patients with indication for anti-HBV therapy - In
patients with indications for treatment of chron-
ic hepatitis B, starting antiretroviral therapy is
recommended independently of the CD4+ count
and of the other parameters, administering teno-
fovir in combination with lamivudine or emtric-
itabine and a third drug or, alternatively, teno-
fovir with another nucleoside active on HBV (tel-
bivudine or entecavir) in addition to another two
antiretrovirals [AII].
TABLE 26 - Antiretroviral therapy in HIV-infected individuals with coinfections with viral infections 
(HBV and HCV).
Coinfection with HCV Coinfection with HBV Cirrhosis
TDM - - Use in patients with decom-
pensated cirrhosis
When to start Recommended at a CD4 level <500 cell/mm3
What to start with (NRTI
backbone)
Avoid didanosine and stavu-
dine; abacavir only after
HLA-B*5701; avoid zidovudi-
ne if the patient is candidate
to Peg-IFN+RBV
Use tenofovir+XTC; do not
use XTC as only drugs active
on HBV
-
What to start to (third drug) Avoid tipranavir and full-dose ritonavir; use nevirapine only as alternative
Use NNRTI or PI or Integrase
inhibitor with a low impact
on insulin resistance
No other indications Saquinavir not indicated in
decompensated cirrhosis; ad-
just dosing in Child-Pugh
classification of Class B*; use
TDM if Child-Pugh classifi-
cation of Class C 
Management of first failure
and successive or alternative
treatment strategies
- Do not discontinue anti-HBV
drugs if staging is >F2 accor-
ding with METAVIR
-
*Caution and monitoring of side effects in the case of hepatic impairment (Child-Pugh >7 points) when efavirenz, lopinavir/r, raltegravir, maraviroc are used;
in patients with severe hepatic impairment increasing levels of plasma concentration of efavirenz and maraviroc have been observed [BIII]. Use atazanavir
at dosing of 300 mg daily (without ritonavir) in patients with cirrhosis and Child-Pugh score between 7 and 9 [BII]. In adults with mild hepatic impairment
(Child-Pugh score 5-6 points) the recommended dosing of fosamprenavir is 700 mg BID with ritonavir 100 mg daily [BII]. In adults with moderate hepatic
impairment (Child-Pugh score 7-9 points) the recommended dosing of fosamprenavir is 450 mg BID with ritonavir 100 mg daily
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Liver toxicity in HIV coinfected with hepatitis viruses
Acute viral or drug-related hepatitis SpeciÞc protocols
Stop treatment
No
No
Yes
Yes
Yes
No
Continue cART with intensive follow-up with at least monthly controls of hepatic
parameters and investigate causes of LEE including liver biopsy
Consider HBV reaction and
maintain HBV therapyHBsAg+ and HBV-DNA+
Lactic acidosis
Hypersensitivity reaction (HSR)
Liver enzyme elevation (LEE) >10-fold upper
normal limits and at least 5-fold basal values
Jaundice or signs of liver failure
FIGURE 3 -Management of liver toxicity in HIV-infected individuals treated with antiretrovirals.
Tuberculosis
The critical passages regarding the use of com-
bination antiretroviral therapy (cART) in subjects
with tuberculosis are:
- Optimal timing of cART initiation with respect
to the tuberculosis treatment.
- The selection of antiretroviral drugs to be ad-
ministered with the tuberculosis therapy on the
basis of assessment of potential pharmacoki-
netic interactions and possible cumulative tox-
icity.
- The risk of developing an immune reconstitu-
tion (inflammatory) syndrome (IRIS) after ini-
tiation of cART and its management.
Opportunistic Infections
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TABLE 27 - Principles of ARV management in HIV-infected patients with tuberculosis.
Recommendations Comments
When to start Strongly recommended to start cART within three
months from the initiation of tuberculosis therapy,
independently from CD4 count or plasma HIV-RNA
levels
- In patients with CD4 <350 cell/mm3, is recom-
mended to start cART as soon as possible after 2
weeks from the initiation of tuberculosis treatment,
in order to evaluate potential adverse reactions to
the tuberculosis drugs.
- In patients with CD4 between 350 and 500
cell/mm3, an early starting of cART is recommen-
ded (between 2 weeks and 2 months from the ini-
tiation of tuberculosis treatment)
- In patients with CD4 >500 cell/mm3, the optimal
timing of cART initiation should be evaluated in
the single case, on the basis of cost-effectiveness
assessment.
What to start
with
Use EFV+2NRTI as choice regimen to be combined
with a rifampin-based tuberculosis regimen[BI] 
The use of PI/r or PI, combined with rifampin is
not indicated. Using PI/r or PI (except for unboo-
sted saquinavir) is feasible if combined with rifa-
butine [BII]. All these combinations should be used
in patients with resistance to NNRTIs or in the ca-
se in which NNRTIs are not tolerated.
Immune
reconstitution
syndrome
(IRIS) after
cART initiation 
Delaying cART initiation after the first months from
starting tuberculosis treatment, the incidence and
severity of IRIS could be reduced. This strategy is
not recommended in patients with CD4 <350
cell/mm3 [AI]. Do not discontinue cART in case of
IRIS [AII]
TABLE 28 - Initiation of antiretroviral therapy
during acute opportunistic infection.
Elements which must be considered include the degree of
immuno-suppression, the availability of effective therapy for
O.I.S, pharmacological interactions and cumulative toxi-
city, and the risk of iris
In the absence of obvious contraindications, early initia-
tion of ART in the initial phases of an acute O.I.
Immediate initiation of ART is highly recommended in
patients with opportunistic infections for which effica-
cious specific therapies are lacking, such as cryptospori-
diosis, microsporidiosis, progressive multifocal leukoen-
cephalopathy (PML), localized cutaneous and mucosal
Kaposi sarcoma (KS), multi-resistant herpes simplex in-
fection.
In patients with PCP initiation of ART is highly recom-
mended within 2 weeks of the diagnosis of PCP.
In O.I.s in which the risk of IRIS is higher (tuberculosis,
cryptococcal meningitis, atypical micobacterial infections,
CMV infection), delayed initiation of ART may be consi-
dered.
TABLE 29 - Management of opportunistic infections
during antiretroviral therapy.
Opportunistic Infections Considerations
<12 weeks of ART - Administer anti-O.I. the-
rapy
- Continue ART [AIII]
- Consider IRIS
>12 weeks of ART with vi-
rological suppression and
immunological recovery
- Administer anti-O.I. the-
rapy
- Continue ART [AIII]
- Consider IRIS
Assess whether to modify or
intensify ART in case of sub-
optimal recovery of CD4+
lymphocytes [CIII]
>12 weeks of ART with vi-
rological failure
- Perform resistance test
[AI]
- Administer anti-O.I. the-
rapy
- Modify ART [AI]
ANTIRETROVIRAL THERAPY IN
PREGNANCY
General aspects of antiretroviral treatment
during pregnancy
Many aspects of antiretroviral therapy in preg-
nancy are as yet unclear due to the difficulty of
conducting randomized clinical studies in this
setting and the difficulty of responding to partic-
ular clinical questions through controlled clini-
cal or observational studies. In particular, there is
no evidence to guide: the optimal timing anti-
retroviral treatment initiation in pregnancy for
women who have no other indication for the
treatment, which choice of drugs and regimens is
safe to continue during the pregnancy, and what
is the long-term impact of antiretroviral therapy
during pregnancy on survival.
Approach to antiretroviral therapy in preg-
nancy
The recommended therapeutic approach is based
on the combined administration of ante partum
and intra partum maternal therapy and on an-
tiretroviral prophylaxis in the newborn. This
therapeutic schema should be applied to all preg-
nant women with HIV, independent of the CD4
and HIV-RNA values. Where, due to late access
to treatment, the ante partum or intra partum
therapy cannot be delivered, administration of
the remaining components of the therapeutic
schema is fundamental.
It is necessary to consider separately women with
maternal indications for antiretroviral therapy
and those whose sole indication is the prevention
of vertical transmission.
Principal therapeutic scenarios
Pregnant women with maternal indication for
antiretroviral treatment must receive a combi-
nation regimen of potency analogous to that rec-
ommended in non-pregnant women. If the
woman is not yet undergoing treatment and there
is indication for immediate treatment, it must be
initiated as soon as possible. For women with
no indication for antiretroviral therapy, the gen-
eral recommendation is to administer, in all cas-
es, a potent combination regimen, as combina-
tion regimens have been found to be the most ef-
fective in preventing vertical transmission.
Independent of the individual indication for an-
tiretroviral therapy in pregnancy (presence or oth-
erwise of the maternal indication for treatment
in addition to prevention of vertical transmis-
sion), the use of antiretroviral mono-therapy in
pregnancy should be considered inadequate due
to its suboptimal antiviral efficacy, the higher risk
of development of resistance, and the greater ef-
ficacy of the combined therapy in preventing ver-
tical transmission.
Pregnancy is characterized by significant physi-
ological changes operating at different levels on
absorption, distribution, metabolism and elimi-
nation of drugs. Reduced plasma levels of drugs
in pregnancy have been reported by diverse au-
thors, especially in the third trimester, most fre-
quently protease inhibitors, which show greater
variability than NRTI and NNRTI.
Monitoring plasmatic drug levels
In general, plasmatic drug level monitoring is
not recommended (TDM) in all pregnant women
with HIV undergoing treatment, but should be
considered in particular situations (e.g.: patholo-
gies or concomitant treatments which can sig-
nificantly interfere with the metabolism, drugs or
regimens particularly those for which there is no
available data during pregnancy, toxicity or in-
efficacy of unclear cause, need to precisely de-
fine the levels relative to the presence of resist-
ance, etc.). For the management of these prob-
lems, increasingly interesting and growing in
complexity, please refer to the specific section
dedicated to Pharmacological Monitoring and
Interactions.
Virological monitoring during pregnancy: vi-
ral load and resistance
Virological objectives of antiretroviral treat-
ment in pregnancy
Viral load monitoring in pregnancy is of partic-
ular relevance as the maternal viral load is an
independent determinant of vertical transmis-
sion. 
It is thus particularly important to maintain the
viral load undetectable in women at the begin-
ning of the pregnancy and to achieve viral sup-
pression of HIV as rapidly as possible to unde-
tectable levels in women commencing treatment
during pregnancy.
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Viral load monitoring may be performed every
two-three months in women on stable therapy
and with undetectable HIV at baseline, while in
women commencing treatment or requiring mod-
ification during pregnancy closer monitoring of
response to treatment is advised. 
An HIV-RNA assessment is recommended in all
women at about week 34-36 of gestation.
Therapeutic failure
In the presence of therapeutic or virological fail-
ure, it is necessary to rapidly modify the treat-
ment in order to guarantee the lowest possible
levels of viral load at the time of delivery. 
To his end, a resistance test to guide the choice
of treatment is highly recommended.
Performance of resistance testing
The use of the resistance assay during pregnan-
cy, follows the general directives regarding adults
a resistance test is recommended in all women
not yet on treatment and in all those undergoing
treatment with a confirmed detectable RNA. 
The test must be ordered in a timely manner, and
optimal period for delineation of resistances and
choice the treatment in pregnancy is the pre-con-
ception period.
Antiretroviral therapy in women already un-
dergoing treatment at conception
Ideally, the regimen at conception should have
been selected in the pre-conception period ac-
cording to criteria which assure safe usage in
pregnancy, so that modification or interruption
is not required in the early weeks of gestation. 
In prescribing potentially teratogen drugs (e.g.
efavirenz) to women of reproductive age or oth-
er regimens or drugs characterised by addition-
al risk of toxicity in pregnancy (e.g. lactic acido-
sis, hepatotoxicity, diabetes), it is necessary to
consider the possibility of an unplanned preg-
nancy and individually assess the risk/benefit of
treatment relative to the risk of unplanned preg-
nancy. 
In women undergoing antiretroviral treatment
with unplanned pregnancy, the regimen must be
re-assessed as soon as possible in order to deter-
mine its safety for use in pregnancy.
Antiretroviral treatment in women who
have never received antiretrovirals prior to
pregnancy
Choice of the treatment regimen
Where there is a maternal indication for treat-
ment, it must commence as soon as possible, al-
so in the first trimester, using a potent regime of
a combination of drugs which has the best evi-
dence for safety in pregnancy.
Where the indication for treatment is solely for
prophylaxis of vertical transmission, it is possi-
ble to consider and discuss with the patient ini-
tiation of treatment after the first trimester, but it
is necessary to consider that in the absence of
treatment there is a risk of ante partum trans-
mission.
Timing of starting treatment
It is not possible to recommend, on the basis of
the available evidence, an optimal timing for
starting of the antiretroviral treatment in preg-
nancy for women with no personal indication
for treatment [9], but the trimester for initiation
of the treatment must guarantee a therapy du-
ration sufficient to achieve complete viral sup-
pression in the final phases of the pregnancy, al-
so considering the possibility that the duration
of the pregnancy may be reduced by the risk of
pre-term birth.
Potency of the regimen
In all women, including those with no personal
indication for treatment, the potency of the
regime must be adequate to achieve complete vi-
ral suppression, and in general, combination reg-
imens must used at the same potency of those
recommended for the treatment of all adults. In
the case of women with viral loads below 1000
copies/mL in the absence of treatment, contro-
versy remains as to whether regimens of lesser
potency than those used for treatment of adults
are to be recommended.
Interruption of treatment
In the case of interruption of antiretroviral treat-
ment during pregnancy, treatment interruption
must be immediate and simultaneous for all
drugs in cases of severe and life threatening tox-
icity or grave hyperemesis. In case of elective in-
terruption, in order to prevent the selection of re-
Italian Guidelines for the use of antiretroviral drugs and the diagnostic-clinical management of people with HIV-1 infection 137
→
sistant strains, if agents with a long half-life are
part of the regimen (e.g. NNRTI, non nucleoside
analogues), it is strongly recommended the se-
quential discontinuation of drugs with long half
lives first, with continued administration of oth-
er regimen components for a period of time suf-
ficient to guarantee triple antiretroviral coverage
as NNRTI levels diminish. 
Continued administration of the other drugs for
at least 7 days may be considered sufficient, but
there is notable variability in the time at which
the NNRTIs become undetectable in plasma after
discontinuation. 
Recent Italian data, while limited to a number of
vertical transmission cases and not exclusively
involving HAART therapies but including
monotherapy (10.6%) and dual therapy (20.0%),
suggest that interruptions of treatment in preg-
nancy may constitute a significant risk factor for
mother-to-child HIV transmission.
POST-EXPOSURE PROPHYLAXIS
Indications for post-exposure prophylaxis
- PEP must be initiated as soon as possible after
exposure, preferably within 1-4 hours, and no
later than 48 hours [AII].
- Exposed subjects who have initiated PEP must
be evaluated by an expert within 48-72 hours
of treatment initiation [AIII].
- In those cases where the serostatus of the
source patient is unknown and the source pa-
tient is available, an targeted epidemiological
investigation should be conduced and a sero-
logical test performed, once consent has been
obtained; the result must be rapidly available,
and where available rapid tests should be
used[AIII].
- Where serological testing is not possible in the
time available, commencement of treatment is
recommended with a new visit planned to re-
evaluate transmission risk, once source-patient
test results have been obtained [AIII].
- An exposure source patient who refuses con-
sent to testing must be considered HIV-infect-
ed [AIII].
- Tests based on detection of antigens and anti-
bodies are preferable. Use to bio-molecular
techniques is not indicated for the purpose of
ascertainment of infection [AII].
- Performance of ad hoc tests to determine re-
sistance to the ARVs is not recommended [AIII].
- During initial counseling of the exposed sub-
ject, the risks connected with the specific ex-
posure must be explained in order to facilitate
correct perception of the probability of infec-
tion and facilitate decision-making on PEP up-
take (Tables 1 and 2) [AIII].
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TABLE 30 - Recommendations for offering PEP.
a) OCCUPATIONAL EXPOSURE
Exposure Mode Source Patient
Used needle puncture to vein or artery
Deep lesion with needle or solid cutting device visibly con-
taminated with blood.
HIV+* 
or 
HIV negative but with history or current pathology indica-
tive of very recent at risk exposure (e.g. acute viral hepati-
tis, IST, endocarditis of right heart) 
or 
refusing to consent to serology tests for HIV
Conjunctival contamination with blood or CSF
Exposure to material with elevated viral concentration
(e.g. cultures, concentrated suspensions of virus) in any
modality.
HIV+*
*The risk is significantly reduced if the source is on ARV therapy with consistently undetectable viral loads in recent months.
In situations other than those indicated, PEP may be considered by an expert on the basis of careful assessment of the risk taking into account the efficiency
of transmission connected with the exposure modality and the contagiousness of the source.
→
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b) NON OCCUPATIONAL EXPOSURE
Exposure Mode Source Patient
Anal, vaginal, oral sex
Receptive with internal ejaculation
HIV+*
or
HIV negative but with history or current pathology indica-
tive of very recent at risk exposure (e.g. acute viral hepati-
tis, IST, endocarditis of right heart)
or
Serology for HIV not known in subject with high risk be-
haviour 
or
in the case of rape/sexual violence 
Insertive anal or vaginal sex
Without protection or inefficacious protection
HIV+*
Receptive anal, vaginal, oral sex
No internal ejaculation
no protection
HIV+*
or
in the case of rape/sexual violence
Exchange of syringe or other material in common use for
narcotic consumption 
Independent of the serological state of the source
*The risk is significantly reduced if the source is on ARV therapy with consistently undetectable viral loads in recent months; risk is augmented if trauma is
verified (e.g. traumatic injury after rape), if there is a presence of blood or current STI especially if with ulcerating disease.
In situations other than those indicated, PEP may be considered by an expert on the basis of careful assessment of the risk taking into account the efficiency
of transmission connected with the exposure modality and the contagiousness of the source.
→
Prophylaxis regimes
- PEP must be composed of a three drug combi-
nation regime [AIII].
- PEP must be continued for 28 days [AIII].
- In the case of an HIV positive source, the choice
of drugs must be guided by the resistance pro-
file by genotyping, if available, or from the chart
review [AII].
- The medical history of the exposed and even-
tual interactions with other drugs must be con-
sidered in the choice of the drugs [AIII].
- Any combination of ARV drugs approved for
the treatment of patients with HIV infection
may be used for PEP, with the same con-
traindications, including new drugs which be-
come available in the future [AIII].
- At this time nevirapine is the sole drug whose
use is not recommended, in the presence of al-
ternatives, due to severe toxicity in immune
competent subjects. The use of stavudine and of
abacavir should be reserved solely for those cas-
es without valid alternatives, due to possible se-
rious reactions [AII].
- Pregnancy is not an absolute criterion for ex-
clusion from PEP; the use of efavirenz is not
recommended (possible teratogenicity), stavu-
dine and didanosine (lactic acidosis), indinavir
(hyperbilirubinaemia as birth approaches) [AII].
TABLE 31 - Antiretroviral regimens recommended and alternative for PEP.
Regimes
Recommended regime 2 N(t)RTI + PI/r
Alternative regime* 2 N(t)RTI + INI (Integrase Inhibitor)
*especially in cases of post coital contraception
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